EPHX2 and metabolic dysfunction-associated steatohepatitis: Previous studies have shown that designed multiple ligands of FXR and sEH,[6, 7, 8] PPARα and PPARδ[35] as well as FXR and PPARδ[9, 10] hold potential to achieve superior efficacy in experimental NASH treatment.